Rockwell Medical signs multi-year supply agreement with Innovative Renal Care

WIXOM, Mich. & FRANKLIN, Tenn. - Rockwell Medical, Inc. (NASDAQ:RMTI) has entered into a multi-year service agreement with Innovative Renal Care (IRC) to supply hemodialysis concentrates to IRC’s dialysis centers across the United States, according to a press release statement.

The three-year agreement includes an option for a one-year extension and involves Rockwell Medical providing liquid and dry acid and bicarbonate hemodialysis concentrates, as well as the DAMX45 dry acid concentrate mix system. The system is 510(k) approved for exclusive use with Rockwell’s CitraPure and Dri-Sate dry acid concentrate powders.

The multi-million dollar purchase agreement includes utilization commitments and aims to help IRC reduce storage requirements while maintaining product quality and supply chain continuity.

David Doerr, Chief Executive Officer at IRC, stated that the partnership will help reliably supply their clinics with hemodialysis concentrates, allowing the company to focus on its mission of patient care.

Tim Chole, Senior Vice President and Chief Commercial Officer at Rockwell Medical, noted that the agreement builds upon the company’s reputation for reliable supply chain, high-quality products, and customer service.

Rockwell Medical develops, manufactures, and distributes hemodialysis products to dialysis providers worldwide. IRC is a national provider of kidney care services, working with nephrologists and health systems to care for patients with chronic kidney disease and end-stage renal disease.

Hemodialysis is the most common treatment for end-stage kidney disease and is typically performed in outpatient dialysis centers, hospital-based centers, skilled nursing facilities, or patients’ homes.

In other recent news, Rockwell Medical Inc reported its first-quarter 2025 earnings, revealing a better-than-expected earnings per share (EPS) of -$0.01, surpassing the forecasted -$0.04. However, the company’s revenue came in at $18.9 million, slightly below the anticipated $19.14 million. Despite the revenue shortfall, the company’s strategic focus on expanding its dialysis product portfolio, particularly in the at-home market, reflects a shift towards higher-margin products. Analyst firms noted the company’s earnings performance as a positive surprise, considering the historical challenges in meeting expectations. Additionally, Rockwell Medical is in discussions with its largest customer for a potential contract extension, aiming to maintain some level of service at a reduced scale. The company continues to explore international expansion opportunities, particularly in Latin America, and is actively pursuing new customer acquisitions. Rockwell Medical’s outlook for 2025 remains optimistic, with projected net sales between $65 million and $70 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.